Jason Mann MD, PhD 万杰颂
About Jason Mann MD, PhD 万杰颂
Jason Mann, MD, PhD, serves as the Managing Director of the Ping An Global Voyager Fund and holds various advisory roles in healthcare and life sciences. With extensive experience in strategic advisory positions and a strong academic background, he has contributed significantly to advanced health technology and has been featured in prominent media outlets.
Current Role at PING AN
Jason Mann serves as the Managing Director of the Ping An Global Voyager Fund and Voyager Partners since 2021. In this role, he focuses on identifying and investing in advanced health technology opportunities. His leadership at Ping An involves strategic decision-making and fostering partnerships that align with the fund's objectives.
Work at Guidepoint
Since 2019, Jason Mann has been the Asia Healthcare Lead at Guidepoint. In this position, he provides insights and expertise on healthcare trends and investment opportunities in the Asian market, leveraging his extensive experience in the healthcare sector.
Education and Expertise
Jason Mann holds a Doctor of Medicine (MD) and a Ph.D. in Cancer Biology from Vanderbilt University. He also earned an A.B. in East Asian Studies and Pre-Medicine from Harvard University. His educational background equips him with a strong foundation in both medical and scientific research.
Strategic Advisory Roles
Throughout his career, Jason Mann has held various strategic advisory roles in multiple organizations. He has advised CEOs and senior management at companies such as Aleva Neurotherapeutics, Novo Holdings, and Fresenius Medical Care, focusing on global and Asian markets. His advisory work spans healthcare and life sciences, emphasizing growth and innovation.
Media Presence and Publications
Jason Mann has been featured in various media outlets, including Bloomberg Businessweek, Reuters, and The Wall Street Journal. He has published 15 peer-reviewed scientific papers and book chapters, contributing to the academic and professional discourse in healthcare and cancer research.